In vitro interactions of coumarins with iron

Biochimie

Volumn 92, Issue 9, 2010, Pages 1108-1114

  Mladěnka, Přemysl ^a   Macáková, Kateřina ^a   Zatloukalová, Libuše ^a   Řeháková, Zuzana ^a   Singh, Brajendra K ^b   Prasad, Ashok K ^b   Parmar, Virinder S ^b   Jahodář, Luděk ^a   Hrdina, Radomír ^a   Saso, Luciano ^c  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF DELHI   (India)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antioxidant; Chelation; Coumarin; Ferrozine; Iron

Indexed keywords

4 METHYLESCULETIN; 7,8 DIHYDROXY 4 METHYLCOUMARIN; COUMARIN DERIVATIVE; DEFEROXAMINE; FERROZINE; IRON; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; IN VITRO STUDY; IRON CHELATION; PH; SPECTROPHOTOMETRY;

ANTIOXIDANTS; COUMARINS; FERROZINE; HYDROGEN-ION CONCENTRATION; IRON; IRON CHELATING AGENTS; MOLECULAR STRUCTURE;

EID: 77955843787     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.03.025     Document Type: Article

References (34)

1. Borges F., Roleira F., Milhazes N., Santana L., Uriarte E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr. Med. Chem. 2005, 12:887-916.
2. Bhattacharyya S.S., Paul S., Mandal S.K., Banerjee A., Boujedaini N., Khuda-Bukhsh A.R. A synthetic coumarin (4-methyl-7 hydroxy coumarin) has anti-cancer potentials against DMBA-induced skin cancer in mice. Eur. J. Pharmacol. 2009, 614:128-136.
3. Campos-Toimil M., Orallo F., Santana L., Uriarte E. Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives. Bioorg. Med. Chem. Lett. 2002, 12:783-786.
4. Di Braccio M., Grossi G., Roma G., Grazia Signorello M., Leoncini G. Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins. Eur. J. Med. Chem. 2004, 39:397-409.
5. Fylaktakidou K.C., Hadjipavlou-Litina D.J., Litinas K.E., Nicolaides D.N. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr. Pharm. Des. 2004, 10:3813-3833.
6. Kostova I. Synthetic and natural coumarins as antioxidants. Mini Rev. Med. Chem. 2006, 6:365-374.
7. Hoult J.R., Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmacol. 1996, 27:713-722.
8. Baccard N., Mechiche H., Nazeyrollas P., et al. Effects of 7-hydroxycoumarin (umbelliferone) on isolated perfused and ischemic-reperfused rat heart. Arzneimittelforschung 2000, 50:890-896.
9. Chang T.H., Adachi H., Okuyama T., Zhang K.Y. Effects of 3'-angeloyloxy-4'-acetoxy-3',4'-dihydroseselin on myocardial dysfunction after a brief ischemia in anesthetized dogs. Zhongguo Yao Li Xue Bao 1994, 15:388-391.
10. Halliwell B., Gutteridge J. Free Radicals in Biology and Medicine 1999, Oxford University Press, New York. third ed.
11. Mladenka P., Hrdina R., Hubl M., Simunek T. The fate of iron in the organism and its regulatory pathways. Acta Medica (Hradec Kralove) 2005, 48:127-135.
12. Ambrosio G., Zweier J.L., Jacobus W.E., Weisfeldt M.L., Flaherty J.T. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation 1987, 76:906-915.
13. Chevion M., Jiang Y., Har-El R., Berenshtein E., Uretzky G., Kitrossky N. Copper and iron are mobilized following myocardial ischemia: possible predictive criteria for tissue injury. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1102-1106.
14. Laughton M.J., Halliwell B., Evans P.J., Hoult J.R. Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochem. Pharmacol. 1989, 38:2859-2865.
15. Cheng Z., Li Y. What is responsible for the initiating chemistry of iron-mediated lipid peroxidation: an update. Chem. Rev. 2007, 107:748-766.
16. Fort D.J., Stover E.L., Propst T., Hull M.A., Bantle J.A. Evaluation of the developmental toxicities of coumarin, 4-hydroxycoumarin, and 7-hydroxycoumarin using FETAX. Drug Chem. Toxicol. 1998, 21:15-26.
17. Pedersen J.Z., Oliveira C., Incerpi S., et al. Antioxidant activity of 4-methylcoumarins. J. Pharm. Pharmacol. 2007, 59:1721-1728.
18. Parmar V.S., Singh S., Boll P.M. Carbon-13 nuclear magnetic resonance spectroscopy of 4-methylcoumarins (4-methyl-2H-1-benzopyran-2-ones). Magn. Reson. Chem. 1988, 26:430-433.
19. Stookey L.L. Ferrozine - a new spectrophotometric reagent for iron. Anal. Chem. 1970, 42:779-781.
20. Cornell R., Schwertmann U. The Iron Oxides 2003, Wiley-VCH, Weinheim.
21. Liu Z.D., Hider R.C. Design of clinically useful iron(III)-selective chelators. Med. Res. Rev. 2002, 22:26-64.
22. Whitnall M., Richardson D.R. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol. 2006, 13:186-197.
23. Miethke M., Marahiel M.A. Siderophore-based iron acquisition and pathogen control. Microbiol. Mol. Biol. Rev. 2007, 71:413-451.
24. Perron N.R., Brumaghim J.L. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell. Biochem. Biophys. 2009, 53:75-100.
25. Schweigert N., Zehnder A.J., Eggen R.I. Chemical properties of catechols and their molecular modes of toxic action in cells, from microorganisms to mammals. Environ. Microbiol. 2001, 3:81-91.
26. Kalinowski D.S., Richardson D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57:547-583.
27. Paya M., Halliwell B., Hoult J.R. Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals. Biochem. Pharmacol. 1992, 44:205-214.
28. Kaneko T., Baba N., Matsuo M. Protection of coumarins against linoleic acid hydroperoxide-induced cytotoxicity. Chem. Biol. Interact. 2003, 142:239-254.
29. Afanas'ev I.B., Dorozhko A.I., Brodskii A.V., Kostyuk V.A., Potapovitch A.I. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem. Pharmacol. 1989, 38:1763-1769.
30. Mira L., Fernandez M.T., Santos M., Rocha R., Florencio M.H., Jennings K.R. Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. Free Radic. Res. 2002, 36:1199-1208.
31. Arora A., Nair M.G., Strasburg G.M. Structure-activity relationships for antioxidant activities of a series of flavonoids in a liposomal system. Free Radic. Biol. Med. 1998, 24:1355-1363.
32. Raj H.G., Sharma R.K., Garg B.S., et al. Mechanism of biochemical action of substituted 4-methylbenzopyran-2-ones. Part 3: a novel mechanism for the inhibition of biological membrane lipid peroxidation by dioxygenated 4-methylcoumarins mediated by the formation of a stable ADP-Fe-inhibitor mixed ligand complex. Bioorg. Med. Chem. 1998, 6:2205-2212.
33. Mladenka P., Kalinowski D.S., Haskova P., et al. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chem. Res. Toxicol. 2009, 22:208-217.
34. Mladenka P., Zatloukalova L., Simunek T., et al. Direct administration of rutin does not protect against catecholamine cardiotoxicity. Toxicology 2009, 255:25-32.